Integrated Diagnostics Holdings PLC Appointment of a Broker (0923S)
March 07 2019 - 2:02AM
UK Regulatory
TIDMIDHC
RNS Number : 0923S
Integrated Diagnostics Holdings PLC
07 March 2019
Integrated Diagnostics Holdings Plc
Company Announcement
7 March 2019
Appointment of J.P. Morgan Cazenove as Corporate Broker
(Cairo and London) - Integrated Diagnostics Holdings ("IDH" or
"the Company"), a leading consumer healthcare company with
operations in Egypt, Jordan, Sudan and Nigeria, announced today
that it has appointed J.P. Morgan Cazenove as Corporate Broker.
-Ends-
About Integrated Diagnostics Holdings
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg and Al Mokhtabar in Egypt, as
well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in
Sudan) and Echo-Scan (Nigeria). A long track record for quality and
safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of over
1,400 diagnostics tests. From its base of 405 branches as of 30
June 2018, IDH will continue to add laboratories through a Hub,
Spoke and Spike business model that provides a scalable platform
for efficient expansion. Beyond organic growth, the Group's
expansion plans include acquisitions in new Middle Eastern and
African markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH has been a Jersey-registered
entity with a Standard Listing on the Main Market of the London
Stock Exchange (ticker: IDHC) since May 2015.
IDH's forward-looking strategy rests on leveraging its
established business model to achieve four key strategic goals,
namely: (1) continue to expand customer reach; (2) increase the
number of tests per patient; (3) expand into new geographic markets
through selective, value-accretive acquisitions; and (4) introduce
new medical services by leveraging the Group's network and
reputable brand position. Learn more at idhcorp.com.
Contacts
IDH +20 (0)2 3345 5530
Sherif El-Ghamrawi, Investor Relations +20 (0)10 0447 8699
Director sherif.elghamrawi@idhcorp.com
Hudson Sandler (International Media
relations) +44 (0) 207 796 4133
Dan de Belder idh@hudsonsandler.com
Bertie Berger
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPSSDFWMFUSEDD
(END) Dow Jones Newswires
March 07, 2019 02:02 ET (07:02 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2023 to Apr 2024